9.00 – 9.05 am – Dr Guillaume VETTER-GENOUD (Director of Quest for health Startup Incubator), Pr Pierre FUMOLEAU (Scientific Director of Cancéropôle Est), Dr Marie-Julie TILLY (Project manager at Cancéropôle Est)
Opening

9.05 – 9.30 am – Pr Pierre FUMOLEAU – Scientific Director of Cancéropôle Est
Major developments and progress in oncology made over the past decade

9.30 – 9.45 am – Msc Mehdi CHELBI – CEO of BiPER Therapeutics
Translational approach for First-in-class therapeutics : Internal data –  real-world data and AI – which strategy to adopt?
BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancers and life-threatening diseases. Our first clinical candidate BPR001-615 is a first-in-class small molecule to treat gastro-intestinal tumors by pushing cancer cells to burn out. BPR001 is a selective inhibitor of BiP/GRP78, a key protein involved in cancer cells survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of BIP+ patients through a precision medicine approach based on a simple blood test. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standards of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001-615 administered orally in monotherapy outperforms 1st line chemotherapy 5FU (Folfox) in gastro-intestinal cancer models

9.45 – 10.00 am – Msc Sébastien VACHENC – CEO of Sagacity Health
Intratumoral strenghts, new players… Toward a paradigm shift in oncology
Sagacity Health is a cutting-edge AI-Biotech company at the forefront of the convergence between AI and Biotechnology, specializing in the exploration of intratumoral microbiota, a key but unknown driver of treatment resistance in oncology. Founded in 2025 by a multidisciplinary European team with deep expertise in pharmaceutical and biotech industries, we are developing a unique agentic AI platform to decipher the dynamic interactions between microbes, tumors, and therapies, thereby reinventing drug discovery. With a strong European ambition, Sagacity Health is emerging as a leading player in pharmacomicrobiomics in oncology, turning therapeutic failures into opportunities and paving the way for precision medicine that integrates the microbial dimension.

10.00 – 10.15 am – Dr Meddy EL ALAOUI  – CEO of AbTx
Smaller ADC formats based on Therano Stick ™ technology could make the difference for solid tumors!
AbTx is a next-generation pure-play biotech company deploying a novel ADC platform (Therano Stick™) to develop differentiated antibody-drug conjugates (ADCs) and improve their therapeutic index (efficacy/safety). Although ADCs have evolved over the past 40 years, poor solid tumor penetration and long half-life still limit their clinical impact, particularly in pancreatic cancer. Using AbTx’s Therano Stick™ technology, smaller ADCs such as antibody fragment conjugates (FDCs) are generated, offering improved tumor access, faster clearance, and enhanced cytotoxic activity. The Therano Stick™ platform employs enzymatic conjugation via bacterial transglutaminase (mTG), combined with a patented Q-Tag system, to enable site-specific conjugation across multiple antibody formats (full-length, Fab, scFv, VHH). Additionally, AbTx aims to expand its technology to develop dual cytotoxic payload ADCs through enzymatic conjugation, further enhancing therapeutic potential.

 10.15- 10.30 am – Dr Albin JEANNE – CEO of Apmonia Therapeutics
Apmonia Tx – Breaking boundaries in cancer by targeting its microenvironment 
Apmonia Tx is a leading French company offering a breakthrough technology by attacking extracellular matrix proteins as a new oncology class. At the convergence of several scientific and technological advances, Apmonia Tx is developing both a unique in silico discovery platform [powered by virtual screening and AI], and a portfolio of drug candidates. Flagship product is a tumor microenvironment modulator that blocks the interaction between thrombospondin-1 (TSP-1) and CD47 receptors. It is ready to enter Phase 1/2a trial in several advanced solid tumors (CTA/IND-ready).

10.30 – 10.45 am – Dr Jean-Marc LIMACHER – Co-Founder, Chairman, CMO of Odimma Therapeutics
ODI-2001: A new platform for personalized cancer immunotherapy
Odimma Therapeutics is an Alsatian start-up working in the field of personalized cancer immunotherapy. The company is developing a next-generation immunization platform based on artificial intelligence and the use of synthetic DNA.

10.45 – 11.00 am – Florent GROS – CEO, Co-Founder of Priothera
Priothera is redefining the standard of care in hemato-oncology by unlocking the full potential of cell therapies.
While cell therapies have transformed cancer treatment, major challenges remain, especially for patients with AML, a disease still responsible for 50,000 deaths every year worldwide.
Priothera’s lead candidate, mocravimod, is a breakthrough immunomodulator designed to both boost the anti-cancer power of cell therapies (including stem cell transplantation and CAR-T) and significantly reduce the severe side effects that limit their use and compromise patient survival.
Backed by impressive preliminary clinical results, mocravimod is now advancing into the Phase 3 MO-TRANS trial marking a major step toward changing the future of AML treatment.